{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:46Z","timestamp":1792787926279,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Education Chunhui Program Cooperative Research Project","award":["HZKY20220029"],"award-info":[{"award-number":["HZKY20220029"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473199"],"award-info":[{"award-number":["82473199"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation","award":["L244024"],"award-info":[{"award-number":["L244024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HER2 overexpression or ERBB2 amplification represents an important molecular feature of urothelial carcinoma (UC) and has been associated with differential responses to immune checkpoint inhibitors (ICIs). However, the tumor microenvironmental (TME) features associated with HER2-defined UC and their potential relationship with ICI responsiveness remain incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Tumor tissues from 52 UC patients treated with ICIs monotherapy at our center underwent multiplex immunofluorescence (IF) staining to evaluate immune cell infiltration and immune checkpoint protein expression. In parallel, transcriptomic and somatic mutation data from 408 UC cases in The Cancer Genome Atlas (TCGA) were analyzed. Differential gene expression and pathway enrichment analyses were performed based on HER2 copy number status (GISTIC score\u2009\u2265\u20092 for amplification). The xCell algorithm was used to estimate immune cell infiltration in bulk RNA-seq data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the institutional cohort, HER2-positive tumors showed numerically lower objective response rate (ORR) and disease control rate (DCR) than HER2-negative tumors, although these differences were not statistically significant. Multiplex IF analysis revealed reduced infiltration of CD4\u207a T cells, CD8\u207a T cells, and CD20\u207a B cells in HER2-positive tumors. PD-1 and STING expression were also lower in HER2-positive tumors, whereas LAG-3, TIM-3, CTLA-4, and PD-L1 showed non-significant downward trends. In the TCGA-BLCA cohort, ERBB2-amplified tumors showed downregulation of immune-related pathways and reduced inferred infiltration of multiple immune cell populations, including T cells, dendritic cells, B cells, NK cells, and macrophages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HER2-positive UC in the institutional IHC-defined cohort and ERBB2-amplified UC in the TCGA cohort were associated with reduced adaptive immune infiltration and attenuated immune-related signaling. These findings support the presence of an immune-cold phenotype in HER2-defined UC and provide hypothesis-generating evidence for further investigation of biomarker-guided combination strategies integrating HER2-targeted therapy with immune checkpoint blockade.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16157-1","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:05:33Z","timestamp":1779084333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Features of tumor microenvironment in HER2-positive urothelial carcinoma and its implications for immunotherapy resistance"],"prefix":"10.1186","volume":"26","author":[{"given":"Jiazhi","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengnan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"1","key":"16157_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"6924","key":"16157_CR2","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature01392","volume":"421","author":"HS Cho","year":"2003","unstructured":"Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421(6924):756\u201360.","journal-title":"Nature"},{"key":"16157_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.pharmthera.2019.03.010","volume":"199","author":"E Cocco","year":"2019","unstructured":"Cocco E, Lopez S, Santin AD, Scaltriti M. Prevalence and role of HER2 mutations in cancer. Pharmacol Ther. 2019;199:188\u201396.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"16157_CR4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/j.1460-2075.1996.tb00356.x","volume":"15","author":"D Karunagaran","year":"1996","unstructured":"Karunagaran D, Tzahar E, Beerli RR, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 1996;15(2):254\u201364.","journal-title":"EMBO J"},{"issue":"1","key":"16157_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.12998\/wjcc.v3.i1.42","volume":"3","author":"T Matsuoka","year":"2015","unstructured":"Matsuoka T, Yashiro M. Recent advances in the HER2 targeted therapy of gastric cancer. World J Clin Cases. 2015;3(1):42\u201351.","journal-title":"World J Clin Cases"},{"key":"16157_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.858865","volume":"12","author":"Y Fan","year":"2022","unstructured":"Fan Y, Li Q, Shen Q, et al. Head-to-head comparison of the expression differences of NECTIN-4, TROP-2, and HER2 in urothelial carcinoma and its histologic variants. Front Oncol. 2022;12:858865.","journal-title":"Front Oncol"},{"issue":"8","key":"16157_CR7","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1093\/oncolo\/oyad070","volume":"28","author":"L Zhou","year":"2023","unstructured":"Zhou L, Shao Z, Liu Y, et al. HER2 expression associated with clinical characteristics and prognosis of urothelial carcinoma in a Chinese population. Oncologist. 2023;28(8):e617\u201324.","journal-title":"Oncologist"},{"key":"16157_CR8","doi-asserted-by":"publisher","first-page":"538-","DOI":"10.1200\/JCO.2024.42.4_suppl.538","volume":"42","author":"D Aggen","year":"2024","unstructured":"Aggen D, Shah N, Zheng J, et al. HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer. Journal of Clinical Oncology. 2024;42:538-.","journal-title":"Journal of Clinical Oncology."},{"issue":"3","key":"16157_CR9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/1078-0432.CCR-21-2210","volume":"28","author":"X Sheng","year":"2022","unstructured":"Sheng X, Chen H, Hu B, et al. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03. Clin Cancer Res. 2022;28(3):489\u201397.","journal-title":"Clin Cancer Res"},{"key":"16157_CR10","doi-asserted-by":"crossref","unstructured":"Suh KJ, Sung JH, Kim JW, Han SH, Lee HS, Min A, Kang MH, Kim JE, Kim JW, Kim SH, Lee JO, Kim YJ, Lee KW, Kim JH, Bang SM, Im SA, Lee JS. EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD- L1 and cytokines release. Oncotarget. 2017;8(38):63901\u201363910.","DOI":"10.18632\/oncotarget.19194"},{"key":"16157_CR11","doi-asserted-by":"publisher","unstructured":"Sheng X, Zeng G, Zhang C, Zhang Q, Bian J, Niu H, Li J, Shi Y, Yao K, Hu B, Liu Z, Liao H, Yu Z, Jin B, Zhao P, Yang T, Liu X, Qin Y, Xue X, Gou X, Huang J, Gu J, Qi X, Zhang L, Ma G, Liu B, Fang J, Jiang S, He Z, Zhou A, Guo J; RC48- C016 Trial Investigators. Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2511648.","DOI":"10.1056\/NEJMoa2511648"},{"key":"16157_CR12","doi-asserted-by":"publisher","unstructured":"Qu M, Wei J, Mo J, Chen J, Wu X, Xu H, Zhou L, Li J, Yan X, Cui C, Si L, Chi Z, Guo J, Sheng X. Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: identifying patients who derive additional benefit from immune combination therapy. Urol Oncol. 2025;000:1\u201312. https:\/\/doi.org\/10.1016\/j.urolonc.2025.12.006.","DOI":"10.1016\/j.urolonc.2025.12.006"},{"issue":"2","key":"16157_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jncc.2023.02.003","volume":"3","author":"H Lei","year":"2023","unstructured":"Lei H, Ling Y, Yuan P, et al. Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer. Journal of the National Cancer Center. 2023;3(2):121\u20138.","journal-title":"Journal of the National Cancer Center"},{"key":"16157_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-1-4939-2742-5_16","volume":"1318","author":"L Faget","year":"2015","unstructured":"Faget L, Hnasko TS. Tyramide signal amplification for immunofluorescent enhancement. Methods Mol Biol. 2015;1318:161\u201372.","journal-title":"Methods Mol Biol"},{"issue":"5","key":"16157_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"issue":"4","key":"16157_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.","journal-title":"Genome Biol"},{"issue":"7","key":"16157_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"key":"16157_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/978-1-0716-0327-7_19","volume":"2120","author":"D Aran","year":"2020","unstructured":"Aran D. Cell-type enrichment analysis of bulk transcriptomes using xCell. Methods Mol Biol. 2020;2120:263\u201376.","journal-title":"Methods Mol Biol"},{"issue":"11","key":"16157_CR19","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","volume":"14","author":"S Aibar","year":"2017","unstructured":"Aibar S, Gonz\u00e1lez-Blas CB, Moerman T, et al. SCENIC: single-cell regulatory network inference and clustering. Nat Methods. 2017;14(11):1083\u20136.","journal-title":"Nat Methods"},{"issue":"23","key":"16157_CR20","doi-asserted-by":"publisher","first-page":"5391","DOI":"10.1158\/1078-0432.CCR-14-2680","volume":"21","author":"SR Lee","year":"2015","unstructured":"Lee SR, Roh YG, Kim SK, et al. Activation of EZH2 and SUZ12 regulated by E2F1 predicts the disease progression and aggressive characteristics of bladder cancer. Clin Cancer Res. 2015;21(23):5391\u2013403.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"16157_CR21","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1158\/1535-7163.MCT-17-0537","volume":"17","author":"C Michaloglou","year":"2018","unstructured":"Michaloglou C, Crafter C, Siersbaek R, et al. Combined inhibition of mTOR and CDK4\/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor-positive breast cancer. Mol Cancer Ther. 2018;17(5):908\u201320.","journal-title":"Mol Cancer Ther"},{"key":"16157_CR22","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.8562","volume":"8","author":"H Yao","year":"2020","unstructured":"Yao H, Lu F, Shao Y. The E2F family as potential biomarkers and therapeutic targets in colon cancer. PeerJ. 2020;8:e8562.","journal-title":"PeerJ"},{"issue":"7787","key":"16157_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen CS, Prokhnevska N, Master VA, et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019;576(7787):465\u201370.","journal-title":"Nature"},{"issue":"5","key":"16157_CR24","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.immuni.2017.10.009","volume":"47","author":"T Ahrends","year":"2017","unstructured":"Ahrends T, Spanjaard A, Pilzecker B, et al. CD4(+) T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity. 2017;47(5):848-61.e5.","journal-title":"Immunity"},{"key":"16157_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1011885","volume":"12","author":"E Scherrer","year":"2022","unstructured":"Scherrer E, Kang A, Bloudek LM, Koshkin VS. HER2 expression in urothelial carcinoma, a systematic literature review. Front Oncol. 2022;12:1011885.","journal-title":"Front Oncol"},{"issue":"4","key":"16157_CR26","first-page":"497","volume":"2","author":"S Miller","year":"1995","unstructured":"Miller S, Hung M. Regulation of HER2\/neu gene-expression (review). Oncol Rep. 1995;2(4):497\u2013503.","journal-title":"Oncol Rep"},{"issue":"1","key":"16157_CR27","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1038\/s41598-020-61567-1","volume":"10","author":"S Han","year":"2020","unstructured":"Han S, Park S, An J, et al. HER2 as a potential biomarker of lymph node metastasis in undifferentiated early gastric cancer. Sci Rep. 2020;10(1):5270.","journal-title":"Sci Rep"},{"issue":"3","key":"16157_CR28","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/cei\/uxac007","volume":"207","author":"S Cen","year":"2022","unstructured":"Cen S, Xu H, Liu Z, Zhao R, Pan H, Han W. Immune microenvironment characteristics and their implications for immune checkpoint inhibitor efficacy in HER2-overexpressing gastric cancer. Clin Exp Immunol. 2022;207(3):318\u201328.","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"16157_CR29","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1093\/annonc\/mds104","volume":"23","author":"YY Janjigian","year":"2012","unstructured":"Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23(10):2656\u201362.","journal-title":"Ann Oncol"},{"issue":"2","key":"16157_CR30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s12029-017-9921-1","volume":"49","author":"P Rajadurai","year":"2018","unstructured":"Rajadurai P, Fatt HK, Ching FY. Prevalence of HER2 positivity and its clinicopathological correlation in locally advanced\/metastatic gastric cancer patients in Malaysia. J Gastrointest Cancer. 2018;49(2):150\u20137.","journal-title":"J Gastrointest Cancer"},{"issue":"Suppl 1","key":"16157_CR31","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/annonc\/12.suppl_1.S3","volume":"12","author":"I Rubin","year":"2001","unstructured":"Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12(Suppl 1):S3-8.","journal-title":"Ann Oncol"},{"issue":"1","key":"16157_CR32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1186\/s12885-018-4613-1","volume":"18","author":"AA Rom\u00e1n-Rosales","year":"2018","unstructured":"Rom\u00e1n-Rosales AA, Garc\u00eda-Villa E, Herrera LA, Gariglio P, D\u00edaz-Ch\u00e1vez J. Mutant p53 gain of function induces HER2 over-expression in cancer cells. BMC Cancer. 2018;18(1):709.","journal-title":"BMC Cancer"},{"issue":"3","key":"16157_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/ijc.2910570311","volume":"57","author":"J Bartkova","year":"1994","unstructured":"Bartkova J, Lukas J, M\u00fcller H, L\u00fctzh\u00f8ft D, Strauss M, Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer. 1994;57(3):353\u201361.","journal-title":"Int J Cancer"},{"issue":"12","key":"16157_CR34","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","volume":"13","author":"CJ Sherr","year":"1999","unstructured":"Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501\u201312.","journal-title":"Genes Dev"},{"issue":"2","key":"16157_CR35","first-page":"121","volume":"3","author":"H Lei","year":"2023","unstructured":"Lei H, Ling Y, Yuan P, et al. Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer. J Natl Cancer Cent. 2023;3(2):121\u20138.","journal-title":"J Natl Cancer Cent"},{"issue":"2","key":"16157_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030563","volume":"7","author":"S Kidd","year":"2012","unstructured":"Kidd S, Spaeth E, Watson K, et al. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS ONE. 2012;7(2):e30563.","journal-title":"PLoS ONE"},{"issue":"4","key":"16157_CR37","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","volume":"21","author":"I Heras-Murillo","year":"2024","unstructured":"Heras-Murillo I, Ad\u00e1n-Barrientos I, Gal\u00e1n M, Wculek SK, Sancho D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat Rev Clin Oncol. 2024;21(4):257\u201377.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"16157_CR38","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/s41556-019-0352-z","volume":"21","author":"S Wu","year":"2019","unstructured":"Wu S, Zhang Q, Zhang F, et al. HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. Nat Cell Biol. 2019;21(8):1027\u201340.","journal-title":"Nat Cell Biol"},{"issue":"12","key":"16157_CR39","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1016\/j.bbagen.2018.08.013","volume":"1862","author":"A Sadremomtaz","year":"2018","unstructured":"Sadremomtaz A, Mansouri K, Alemzadeh G, Safa M, Rastaghi AE, Asghari SM. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K\/AKT and MAPK\/ERK1\/2 pathway. Biochim Biophys Acta Gen Subj. 2018;1862(12):2688\u2013700.","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"5","key":"16157_CR40","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765\u201372.","journal-title":"Int Immunol"},{"issue":"2","key":"16157_CR41","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.18632\/oncotarget.13895","volume":"8","author":"Y Dong","year":"2017","unstructured":"Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8(2):2171\u201386.","journal-title":"Oncotarget"},{"issue":"9","key":"16157_CR42","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.7150\/jca.57334","volume":"12","author":"C Ghosh","year":"2021","unstructured":"Ghosh C, Luong G, Sun Y. A snapshot of the PD-1\/PD-L1 pathway. J Cancer. 2021;12(9):2735\u201346.","journal-title":"J Cancer"},{"issue":"1","key":"16157_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58\u201367.","journal-title":"Blood"},{"issue":"1","key":"16157_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10(1):48\u201357.","journal-title":"Nat Immunol"},{"issue":"8","key":"16157_CR45","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1084\/jem.20042028","volume":"201","author":"V Bronte","year":"2005","unstructured":"Bronte V, Kasic T, Gri G, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med. 2005;201(8):1257\u201368.","journal-title":"J Exp Med"},{"key":"16157_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","volume":"52","author":"JS O'Donnell","year":"2017","unstructured":"O\u2019Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1\/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71\u201381.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"16157_CR47","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"issue":"47","key":"16157_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202514600","volume":"12","author":"J Chen","year":"2025","unstructured":"Chen J, Mo J, Wei J, et al. MARCO+ tumor-associated macrophages impede CD8+ t cell immunity to facilitate immunotherapy resistance in renal cell carcinoma. Adv Sci (Weinh). 2025;12(47):e14600.","journal-title":"Adv Sci (Weinh)"},{"key":"16157_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.771210","volume":"12","author":"L Fei","year":"2021","unstructured":"Fei L, Ren X, Yu H, Zhan Y. Targeting the CCL2\/CCR2 axis in cancer immunotherapy: one stone, three birds? Front Immunol. 2021;12:771210.","journal-title":"Front Immunol"},{"issue":"7355","key":"16157_CR50","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature10138","volume":"475","author":"BZ Qian","year":"2011","unstructured":"Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222\u20135.","journal-title":"Nature"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16157-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16157-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16157-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:03:17Z","timestamp":1784041397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16157-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16157"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16157-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"11 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Peking University Cancer Hospital & Institute (Approval No. 2024KT193). All procedures were conducted in accordance with the ethical standards of the institutional research committee and the Declaration of Helsinki. The requirement for informed consent was waived due to the retrospective nature of the study, in accordance with institutional regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Xinan Sheng has the following potential conflicts of interest to disclose: non-profit consultant for Pfizer, Novartis, Astellas, AstraZeneca, Bayer, MSD, RemeGen, and Junshi Biosciences. Jun Guo is a member of the advisory board\/consultant of MSD, Roche, Pfizer, Bayer, Novartis, Simcere, Shanghai Junshi Bioscience, and Oriengene. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"842"}}